Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer by Yuanyuan Shen, Qingling Hua, Menghao Dong, Wei Jin, Xueyang Hu, Kangsheng Gu

Get full text

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer by Miao-Zhen Qiu, Yuxian Bai, Jufeng Wang, Kangsheng Gu, Mudan Yang, Yifu He, Cheng Yi, Yongdong Jin, Bo Liu, Feng Wang, Yu-kun Chen, Wei Dai, Yingyi Jiang, Chuanpei Huang, Rui-Hua Xu, Hui-Yan Luo

Get full text

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study by Jian Zhang, Ping Lu, Hui Zhao, Jianhua Chen, Wei Shi, Xiubao Ren, Yi Hu, Liping Wang, Hongmei Zhang, Chengchu Zhu, Jianping Xiong, Jianying Zhou, Jun Zhao, Yongqian Shu, Caicun Zhou, Xiaorong Dong, Yunpeng Liu, Yunchao Huang, Jian Zhao, Yiping Zhang, Sheng Hu, Xiaoyan Lin, Yueyin Pan, Jiuwei Cui, Lizhu Lin, Kangsheng Gu, Yun Fan, Qun Chen, Gongyan Chen, Zhehai Wang, Fengying Wu, Guangyu An, Shuliang Guo, Xiaodong Jiang, Yongsheng Wang, Jifeng Feng, Jianhua Shi, QiMing Wang, Jianan Huang, Lejie Cao, Jianhua Chang, Zhiyong He, Jian Fang, Faguang Jin, Hongjun Gao, Cuimin Ding, Xiangdong Zhou, Anwen Liu, Jianjin Huang, Beili Gao, Yinglan Chen, Chengping Hu, Zhigao Wang, Xinjing Ma

Get full text